For US Trastuzumab Biosimilars, Development Time Did Not Predict Speed To Market

 
• By Sue Sutter
Race driver pass the finishing point and motion blur backgroud. 3D rendering - Illustration
Speed to approval does not always equate to speed to market. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics